PACS Group, Inc. (PACS)
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-09
$44.60+2.13%
Close 2026-09-09 · 1-day change
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
PACS Group is improving operational efficiency with strong tech solutions. Revenue guidance is steady near $5.7 billion for 2026. Adjusted EBITDA guidance rose to $605-$625 million, showing profit growth. Cash from operations turned positive at $236 million in Q1 2026.
PACS has had recent earnings misses and management volatility. Its valuation is stretched with a PE of 22.14 and EV/EBITDA of 60.28. Operational improvements may stall, risking cash flow and profit targets.
The market prices PACS about 31% above our fair value near $33 with 8.3% revenue growth expected. Our view is cautious as valuation is high despite solid guidance and improving cash flow.
Breaks if: Adjusted EBITDA falls below $605 million in FY26
Continue to grow Adjusted EBITDA with increased full-year 2026 guidance reflecting strong operational performance and acquisitions.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
PACS is a cyclical name in the Healthcare sector, benefiting from recent strong financial results. The current thesis state is intact, supported by management's confidence and recent earnings beats.
The market seems to have a neutral valuation for PACS, with expectations slightly below peers. There is a low fragility tier, indicating that the current pricing does not reflect significant risks.
Management is focused on increasing Adjusted EBITDA and revenue guidance, which they have successfully done in recent quarters. Operating cash flow has improved significantly, but there is a low probability of missing future earnings expectations.
Key factors include the potential for PACS to maintain or raise guidance, as well as the performance of sector bellwethers like HCA and THC. Additionally, broader economic conditions, such as job growth, could impact PACS's performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. The company plans to expand its footprint through strategic acquisitions. Additionally, it reaffirmed and increased revenue guidance for 2026.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA guidance rose from a prior range of $555-$575 million in 2025-Q4 to $640-$660 million in 2026-Q2, reflecting management's increased confidence. The trajectory is delivering with guidance raised twice in 2026.
“Increasing full-year 2026 Adjusted EBITDA guidance to $640 million to $660 million.”
“Increasing full-year 2026 Adjusted EBITDA guidance to $605 million to $625 million.”
“Adjusted EBITDA expected to be in the range of $555 million to $575 million for 2026.”
Breaks if: Operational cash flow falls below $236 million in Q1 2026
Breaks if: Revenue falls below $5.65 billion in FY26
Overall, PACS is positioned well but must navigate potential risks in the near term. Not investment advice.